Hisamitsu Pharmaceutical sees highest patent filings and grants during September in Q3 2023
Hisamitsu Pharmaceutical saw the highest growth of 199% in patent filings and 266% in grants in September in Q3 2023. Compared to Q2 2023, Q3 2023 saw an increase in patent filings by 124% and grants by 132%. GlobalData's DataBook provides a comprehensive analysis of Hisamitsu Pharmaceutical's patent filings and grants. Buy the databook here.Hisamitsu Pharmaceutical has been focused on protecting inventions in Japan(JP) with 17 publications in Q3 2023The Japan(JP) Patent Office dominates the patent filings and grants with nearly 39% filings and 53% grants. The Japan(JP), European Patent Office(EPO), China(CN), and South Korea(KR) patent Office are among the top ten patent offices where Hisamitsu Pharmaceutical is filings its patents. Among the top granted patent authorities, Hisamitsu Pharmaceutical has 53% of its grants in Japan(JP), 20% in European Patent Office(EPO), and 13% in Taiwan(TW). could be the strongest competitor for Hisamitsu Pharmaceutical and secured the top positions according to recent patent publication data.Patents related to climate change and workplace safety lead Hisamitsu Pharmaceutical's portfolioHisamitsu Pharmaceutical has the highest number of patents in climate change followed by, workplace safety and circular economy. For climate change, nearly 29% of patents were filed and 0% of patents were granted in Q3 2023.Cosmetics & toiletries related patents lead Hisamitsu Pharmaceutical portfolio followed by skincare, and packagingHisamitsu Pharmaceutical has highest number of patents in cosmetics & toiletries followed by skincare, packaging, drug delivery devices and petrochemicals. For cosmetics & toiletries, nearly 29% of patents were filed and 22% of patents were granted in Q3 2023.For comprehensive analysis of Hisamitsu Pharmaceutical's filings and grants, buy the databook here.
Access and buy GlobalData’s databook on the latest filings and grants activity for Hisamitsu Pharmaceutical here.
What's Your Reaction?
